| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From Nordic Bioscience A/S,* Herlev, Denmark; Ribe County Hospital, Esbjerg, Denmark; Blodbanken, University Hospital Denmark, Østerbro, Denmark; Neurosearch A/S, Ballerup, Denmark; the Center for Clinical and Basic Research,** Ballerup, Denmark; St. Vincent’s Institute of Medical Research,¶ Melbourne, Australia; and the Department of Medicine,|| Section of Endocrinology, National University Hospital, Oslo, Norway
Patients with defective osteoclastic acidification have increased numbers of osteoclasts, with decreased resorption, but bone formation that remains unchanged. We demonstrate that osteoclast survival is increased when acidification is impaired, and that impairment of acidification results in inhibition of bone resorption without inhibition of bone formation. We investigated the role of acidification in human osteoclastic resorption and life span in vitro using inhibitors of chloride channels (NS5818/NS3696), the proton pump (bafilomycin) and cathepsin K. We found that bafilomycin and NS5818 dose dependently inhibited acidification of the osteoclastic resorption compartment and bone resorption. Inhibition of bone resorption by inhibition of acidification, but not cathepsin K inhibition, augmented osteoclast survival, which resulted in a 150 to 300% increase in osteoclasts compared to controls. We investigated the effect of inhibition of osteoclastic acidification in vivo by using the rat ovariectomy model with twice daily oral dosing of NS3696 at 50 mg/kg for 6 weeks. We observed a 60% decrease in resorption (DPYR), increased tartrate-resistant acid phosphatase levels, and no effect on bone formation evaluated by osteocalcin. We speculate that attenuated acidification inhibits dissolution of the inorganic phase of bone and results in an increased number of nonresorbing osteoclasts that are responsible for the coupling to normal bone formation. Thus, we suggest that acidification is essential for normal bone remodeling and that attenuated acidification leads to uncoupling with decreased bone resorption and unaffected bone formation.
This article has been cited by other articles:
 |
|
 |
|
  U. Valcourt, B. Merle, E. Gineyts, S. Viguet-Carrin, P. D. Delmas, and P. Garnero Non-enzymatic Glycation of Bone Collagen Modifies Osteoclastic Activity and Differentiation J. Biol. Chem., February 23, 2007; 282(8): 5691 - 5703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Helfrich, J. C. Crockett, L. J. Hocking, and F. P. Coxon The Pathogenesis of Osteoclast Diseases: Some Knowns, but Still Many Unknowns IBMS BoneKEy, February 1, 2007; 4(2): 61 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Karsdal and K. Henriksen Osteoclasts Control Osteoblast Activity IBMS BoneKEy, January 1, 2007; 4(1): 19 - 24. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ito, S. Haito, M. Furumoto, Y. Uehata, A. Sakurai, H. Segawa, S. Tatsumi, M. Kuwahata, and K.-i. Miyamoto Unique uptake and efflux systems of inorganic phosphate in osteoclast-like cells Am J Physiol Cell Physiol, January 1, 2007; 292(1): C526 - C534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Piwnica, I. Fernandez, N. Binart, P. Touraine, P. A. Kelly, and V. Goffin A New Mechanism for Prolactin Processing into 16K PRL by Secreted Cathepsin D Mol. Endocrinol., December 1, 2006; 20(12): 3263 - 3278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.J. MARTIN, J.M.W. QUINN, M.T. GILLESPIE, K.W. NG, M.A. KARSDAL, and N.A. SIMS Mechanisms Involved in Skeletal Anabolic Therapies Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 458 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Del Fattore, B Peruzzi, N Rucci, I Recchia, A Cappariello, M Longo, D Fortunati, P Ballanti, M Iacobini, M Luciani, et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment J. Med. Genet., April 1, 2006; 43(4): 315 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Pusch, G Zifarelli, A. R Murgia, A Picollo, and E Babini Channel or transporter? The CLC saga continues Exp Physiol, January 1, 2006; 91(1): 149 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Koh, B. Demiralp, K. G. Neiva, J. Hooten, R. M. Nohutcu, H. Shim, N. S. Datta, R. S. Taichman, and L. K. McCauley Cells of the Osteoclast Lineage as Mediators of the Anabolic Actions of Parathyroid Hormone in Bone Endocrinology, November 1, 2005; 146(11): 4584 - 4596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Henriksen, J. Gram, P. Hoegh-Andersen, R. Jemtland, T. Ueland, M. H. Dziegiel, S. Schaller, J. Bollerslev, and M. A. Karsdal Osteoclasts from Patients with Autosomal Dominant Osteopetrosis Type I Caused by a T253I Mutation in Low-Density Lipoprotein Receptor-Related Protein 5 Are Normal in Vitro, but Have Decreased Resorption Capacity in Vivo Am. J. Pathol., November 1, 2005; 167(5): 1341 - 1348. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
